Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia.

Xiaoxiao LuBruno EmondLaura MorrisonFrederic KinkeadPatrick LefebvreMarie-Hélène LafeuilleWasiulla KhanLinda H WuZaina P QureshiRyan Jacobs

Published in: Patient preference and adherence (2023)

In this real-world analysis, CLL/SLL patients initiating 1L once-daily ibrutinib had >50% higher treatment adherence than those initiating twice-daily acalabrutinib during their LOT. Given the importance of sustained adherence for disease control in CLL/SLL, dosing frequency may be an important consideration for patients and physicians.

Keyphrases

chronic lymphocytic leukemia
end stage renal disease
newly diagnosed
ejection fraction
primary care
physical activity
adipose tissue
patient reported outcomes
metabolic syndrome
replacement therapy
smoking cessation
data analysis